Asset: Selective oral CYP11A1 small-molecule inhibitor
Development Stage: IND enabling stage
Indication: Prostate cancer and multiple solid tumors
Key Asset Highlights:
- Targets CYP11A1, a key upstream steroid synthesis enzyme closely associated with tumor hormone metabolism and malignant progression, presenting a novel differentiated mechanism for solid tumor targeted therapy.
- Delivers potent and selective inhibitory activity against CYP11A1, effectively blocking intratumoral steroid hormone synthesis and suppressing tumor cell proliferation and invasion in hormone-dependent solid tumors.
- Exhibits superior anti-tumor efficacy in preclinical models of castration-resistant prostate cancer, overcoming the drug resistance bottleneck of conventional hormone therapy agents.
- Demonstrates broad anti-tumor potential across multiple solid tumor indications beyond prostate cancer, providing a versatile therapeutic candidate for diverse steroid-dependent malignant tumors.
- Possesses excellent oral bioavailability, ideal pharmacokinetic characteristics and a favorable safety window, supporting convenient oral administration and sustainable clinical long-term medication.
- Protected by a comprehensive and robust intellectual property portfolio, ensuring exclusive and stable global development and commercialization rights for subsequent clinical transformation and market application.
If you are a search & evaluation professional working in a MNC, biopharma, biotech, VC company and interested in this opportunity, please feel free to contact DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
